For most of my investing life, I believed the market rewarded courage. The loudest voices on financial television certainly seemed convinced of it. Every day there was a new revolutionary technology, a new hyper-growth stock, a new industry supposedly destined to change civilization forever. The message was always the same: if I wanted exceptional returns, I had to chase exceptional stories. And for a while, that idea made perfect sense. After all, growth is exciting. Income is boring. Nobody gathers around the water cooler to discuss a utility company raising its dividend by 4%. Nobody posts screenshots of a stable infrastructure fund generating predictable cash flow. Nobody brags at parties about owning a pipeline operator that quietly distributes income every quarter. Instead, people talk about the stock that doubled. The startup that exploded higher. The company that turned a thousand dollars into ten thousand. The financial media loves excitement because excitement generates atten...
For most investors, the stock market is a popularity contest. For me, it's a scavenger hunt. I'm not looking for the stocks everyone already loves. By the time financial television is discussing them nonstop and social media has turned them into cults, the easy money is often gone. The crowd has arrived. The narrative has formed. The expectations are sky-high. I'm looking for something different. I'm looking for catalysts. Specifically, I'm looking for moments when reality is changing faster than Wall Street's perception of reality. That's where pharmaceutical stocks become fascinating. Not because they're easy. Not because they're predictable. And certainly not because they don't occasionally resemble a casino run by molecular biologists. They're fascinating because few sectors create larger disconnects between present value and future value. A biotech company can look worthless today and become enormously valuable tomorrow. Like...